Medroxyprogesterone Acetate for Abnormal Uterine Bleeding Due to Ovulatory Dysfunction: The Effect of 2 Different-Duration Regimens

24 June 2022: Clinical Research

Rukiye Ada Bender ^12ABCDEFG*

DOI: 10.12659/MSM.936727

Med Sci Monit 2022; 28:e936727

Table 1 The demographic data distribution of women in the study.

MPA* administration days	Group A (n=22)		Group B (n=30)		p-value
MPA* administration days	11th & 25th	Min–Max	16th & 25th	Min–Max	p-value
	44.27±7.42	25–55	43.10±6.80	31–54	0.48
	2.86±1.55	0–6	2.43±1.71	0–9	0.29
	2.27±1.20	0–5	1.70±1.02	0–3	0.19
	0.22±0.52	0–2	0.13±0.43	0–2	0.4
	0	0	0.10±0.40	0–2	0.22
	0.36±0.65	0–2	0.50±1.00	0–5	0.69
	2.27±1.20	0–5	1.70±1.02	0–3	0.19
	1.31±1.32	0–5	0.66±1.12	0–3
	0.95±1.04	0–3	1.03±1.03	0–3	0.78
					0.21
Oligomenorrhea	2 (%9)		2 (%6.7)
Heavy menstrual bleeding	5 (%22.7)		7 (%23.3)
Prolonged menstrual bleeding	15 (%68.2)		21 (%70)
					0.21
0–5 mm	3 (%13.6)		5 (%16.7)
5–14 mm	3 (%13.6)		9 (%30)
>14 mm	16 (%72.7)		16 (%53.3)
	11.63±1.77	6.88–14.3	12.27±1.17	8.94–14.40	0.16
	35.67±5.10	23.10–44.10	37.90±3.63	28.40–45.10	0.06
^**	33.30±4.29	26.60–41.90	32.03±3.65	22.30–39.30	0.26
^***	0.98±0.21	0.81–1.77	0.92±0.09	0.77–1.16	0.73
	2.08±0.51	1.15–2.89	1.99±0.49	1.13–2.75	0.52
					0.95
Proliferative endometrium	5 (%22.7)		7 (%23.3)
Irregular proliferation	17 (%77.3)		23 (%76.7)
^* Medroxyprogesterone acetate; ^ activated partial thromboplastin time; ^* international normalized ratio.